Patents by Inventor Keith Goldman
Keith Goldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10064411Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably the pyrethroid permethrin, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: GrantFiled: April 9, 2018Date of Patent: September 4, 2018Assignee: THE HARTZ MOUNTAIN CORPORATIONInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Patent number: 9955696Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably the pyrethroid tetramethrin, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: GrantFiled: August 11, 2016Date of Patent: May 1, 2018Assignee: THE HARTZ MOUNTAIN CORPORATIONInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Publication number: 20170000131Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably the pyrethroid tetramethrin, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: ApplicationFiled: August 11, 2016Publication date: January 5, 2017Inventors: W. Lance Hemsarth, Keith Goldman, ELLEN MCGARVEY
-
Publication number: 20160081330Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably the pyrethroid tetramethrin, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: ApplicationFiled: December 7, 2015Publication date: March 24, 2016Applicant: The Hartz Mountain CorporationInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Patent number: 9247733Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: GrantFiled: January 22, 2015Date of Patent: February 2, 2016Assignee: The Hartz Mountain CorporationInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Publication number: 20150157013Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: ApplicationFiled: January 22, 2015Publication date: June 11, 2015Applicant: THE HARTZ MOUNTAIN CORPORATIONInventors: W. Lance HEMSARTH, Keith GOLDMAN, Ellen MCGARVEY
-
Patent number: 9049860Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: GrantFiled: April 1, 2014Date of Patent: June 9, 2015Assignee: The Hartz Mountain CorporationInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Patent number: 8993613Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: GrantFiled: April 1, 2014Date of Patent: March 31, 2015Assignee: The Hartz Mountain CorporationInventors: W. Lance Hemsarth, Keith Goldman, Ellen McGarvey
-
Publication number: 20140315970Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: ApplicationFiled: April 1, 2014Publication date: October 23, 2014Applicant: THE HARTZ MOUNTAIN CORPORATIONInventors: W. Lance HEMSARTH, Keith Goldman, Ellen McGarvey
-
Publication number: 20140315969Abstract: The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably fipronil, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed.Type: ApplicationFiled: April 1, 2014Publication date: October 23, 2014Applicant: THE HARTZ MOUNTAIN CORPORATIONInventors: W. Lance HEMSARTH, Keith Goldman, Ellen McGarvey
-
Patent number: 8148091Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.Type: GrantFiled: January 19, 2011Date of Patent: April 3, 2012Assignee: Ochsner Clinic FoundationInventors: Thomas Cooper Woods, Corey Keith Goldman
-
Publication number: 20110117584Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.Type: ApplicationFiled: January 19, 2011Publication date: May 19, 2011Inventors: Thomas Cooper Woods, Corey Keith Goldman
-
Patent number: 7879561Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.Type: GrantFiled: April 13, 2009Date of Patent: February 1, 2011Assignee: Ochsner Clinic FoundationInventors: Thomas Cooper Woods, Corey Keith Goldman
-
Publication number: 20090246799Abstract: The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.Type: ApplicationFiled: April 13, 2009Publication date: October 1, 2009Inventors: Thomas Cooper Woods, Corey Keith Goldman